Pathways towards Precision Medicine in Cancer Management Using Genomic Information  

作　　者：Jingwu Xie 

机构地区：[1]Department of Pediatrics, Wells Center for Pediatrics Research, Indiana University School of Medicine

出　　处：《Journal of Genetics and Genomics》2015年第10期515-515,516,共2页遗传学报（英文版）

摘　　要：Cancer research over the last few decades indicates that cancer is a genetic disease. In fact, the discovery of the most advanced targeted therapy of cancer comes from cancer ge- netics/genomics studies. This year marks the 20th anniversary for the invention of imatinib mesylate, which targets primarily the BCR-ABL kinase in Philadelphia chromosome-positive chronic myelogenous leukemia （CML）. Philadelphia chro- mosome is the most significant chromosomal aberration in leukemia, and imayinib mesylate is regarded as the first small molecule targeting mutant kinases in cancer. In the last few years, additional therapeutic drugs have been developed to target mutant EGFR and ALK fusion proteins in lung adeno- carcinomas. Thus, understanding the genomic aberrations has huge impacts on clinical management of cancer.Cancer research over the last few decades indicates that cancer is a genetic disease. In fact, the discovery of the most advanced targeted therapy of cancer comes from cancer ge- netics/genomics studies. This year marks the 20th anniversary for the invention of imatinib mesylate, which targets primarily the BCR-ABL kinase in Philadelphia chromosome-positive chronic myelogenous leukemia （CML）. Philadelphia chro- mosome is the most significant chromosomal aberration in leukemia, and imayinib mesylate is regarded as the first small molecule targeting mutant kinases in cancer. In the last few years, additional therapeutic drugs have been developed to target mutant EGFR and ALK fusion proteins in lung adeno- carcinomas. Thus, understanding the genomic aberrations has huge impacts on clinical management of cancer.

关 键 词：In gene EGFR XPC LUNG 

分 类 号：R730.5[医药卫生—肿瘤]